Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MAIA Biotechnology, Inc. ( (MAIA) ) has provided an update.
On October 27, 2025, MAIA Biotechnology announced its participation in the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, where they presented a trial in progress poster for their THIO-101 Phase 2 clinical trial. The company has enrolled five patients from Taiwan and Turkey in the expansion phase of this trial, which aims to evaluate the anti-tumor activity of ateganosine in combination with immune checkpoint inhibitors for advanced NSCLC patients. This development could offer a promising treatment option for the large and underserved NSCLC patient population, particularly in regions with high lung cancer prevalence due to factors like smoking and air pollution.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. Their lead program involves ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for treating non-small cell lung cancer (NSCLC) patients with telomerase-positive cancer cells.
Average Trading Volume: 596,322
Technical Sentiment Signal: Sell
Current Market Cap: $47.18M
For detailed information about MAIA stock, go to TipRanks’ Stock Analysis page.